<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">31607604</PMID><DateCompleted><Year>2020</Year><Month>07</Month><Day>27</Day></DateCompleted><DateRevised><Year>2024</Year><Month>07</Month><Day>22</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1873-2518</ISSN><JournalIssue CitedMedium="Internet"><Volume>37</Volume><Issue>49</Issue><PubDate><Year>2019</Year><Month>Nov</Month><Day>20</Day></PubDate></JournalIssue><Title>Vaccine</Title><ISOAbbreviation>Vaccine</ISOAbbreviation></Journal><ArticleTitle>Immunogenicity of four doses of oral poliovirus vaccine when co-administered with the human neonatal rotavirus vaccine (RV3-BB).</ArticleTitle><Pagination><StartPage>7233</StartPage><EndPage>7239</EndPage><MedlinePgn>7233-7239</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.vaccine.2019.09.071</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0264-410X(19)31299-X</ELocationID><Abstract><AbstractText Label="BACKGROUND">The RV3-BB human neonatal rotavirus vaccine was developed to provide protection from severe rotavirus disease from birth. The aim of this study was to investigate the potential for mutual interference in the immunogenicity of oral polio vaccine (OPV) and RV3-BB.</AbstractText><AbstractText Label="METHODS">A randomized, placebo-controlled trial involving 1649 participants was conducted from January 2013 to July 2016 in Central Java and Yogyakarta, Indonesia. Participants received three doses of oral RV3-BB, with the first dose given at 0-5&#x202f;days (neonatal schedule) or ~8&#x202f;weeks (infant schedule), or placebo. Two sub-studies assessed the immunogenicity of RV3-BB when co-administered with either trivalent OPV (OPV group, n&#x202f;=&#x202f;282) or inactivated polio vaccine (IPV group, n&#x202f;=&#x202f;333). Serum samples were tested for antibodies to poliovirus strains 1, 2 and 3 by neutralization assays following doses 1 and 4 of OPV.</AbstractText><AbstractText Label="RESULTS">Sero-protective rates to poliovirus type 1, 2 or 3 were similar (range 0.96-1.00) after four doses of OPV co-administered with RV3-BB compared with placebo. Serum IgA responses to RV3-BB were similar when co-administered with either OPV or IPV (difference in proportions OPV vs IPV: sIgA responses; neonatal schedule 0.01, 95% CI -0.12 to 0.14; p&#x202f;=&#x202f;0.847; infant schedule -0.10, 95% CI -0.21 to -0.001; p&#x202f;=&#x202f;0.046: sIgA GMT ratio: neonatal schedule 1.23, 95% CI 0.71-2.14, p&#x202f;=&#x202f;0.463 or infant schedule 1.20, 95% CI 0.74-1.96, p&#x202f;=&#x202f;0.448).</AbstractText><AbstractText Label="CONCLUSIONS">The co-administration of OPV with RV3-BB rotavirus vaccine in a birth dose strategy did not reduce the immunogenicity of either vaccine. These findings support the use of a neonatal RV3-BB vaccine where either OPV or IPV is used in the routine vaccination schedule.</AbstractText><CopyrightInformation>Copyright &#xa9; 2019 The Authors. Published by Elsevier Ltd.. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Cowley</LastName><ForeName>Daniel</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Enteric Diseases, Murdoch Children's Research Institute, Parkville, Victoria, Australia; Department of Paediatrics, The University of Melbourne, Parkville, Victoria, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sari</LastName><ForeName>Rini Mulia</ForeName><Initials>RM</Initials><AffiliationInfo><Affiliation>Bio Farma PT, Bandung, Indonesia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Handley</LastName><ForeName>Amanda</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Enteric Diseases, Murdoch Children's Research Institute, Parkville, Victoria, Australia; Medicines Development for Global Health, Melbourne, Victoria, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Watts</LastName><ForeName>Emma</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Enteric Diseases, Murdoch Children's Research Institute, Parkville, Victoria, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bachtiar</LastName><ForeName>Novilia S</ForeName><Initials>NS</Initials><AffiliationInfo><Affiliation>Bio Farma PT, Bandung, Indonesia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>At Thobari</LastName><ForeName>Jarir</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Departments of Pharmacology and Therapy, Public Health and Nursing, Universitas Gadjah Mada, Yogyakarta, Indonesia; Paediatric Research Office, Department of Paediatrics Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada, Yogyakarta, Indonesia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Satria</LastName><ForeName>Cahya Dewi</ForeName><Initials>CD</Initials><AffiliationInfo><Affiliation>Paediatric Research Office, Department of Paediatrics Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada, Yogyakarta, Indonesia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bogdanovic-Sakran</LastName><ForeName>Nada</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Enteric Diseases, Murdoch Children's Research Institute, Parkville, Victoria, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nirwati</LastName><ForeName>Hera</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Departments of Microbiology, Public Health and Nursing, Universitas Gadjah Mada, Yogyakarta, Indonesia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Orsini</LastName><ForeName>Francesca</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Clinical Epidemiology and Biostatistics Unit and the Melbourne Children's Trials Centre, Murdoch Children's Research Institute, Parkville, Victoria, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Katherine J</ForeName><Initials>KJ</Initials><AffiliationInfo><Affiliation>Department of Paediatrics, The University of Melbourne, Parkville, Victoria, Australia; Clinical Epidemiology and Biostatistics Unit and the Melbourne Children's Trials Centre, Murdoch Children's Research Institute, Parkville, Victoria, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kirkwood</LastName><ForeName>Carl D</ForeName><Initials>CD</Initials><AffiliationInfo><Affiliation>Enteric Diseases, Murdoch Children's Research Institute, Parkville, Victoria, Australia; Department of Paediatrics, The University of Melbourne, Parkville, Victoria, Australia; Bill and Melinda Gates Foundation, Seattle, WA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Soenarto</LastName><ForeName>Yati</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Paediatric Research Office, Department of Paediatrics Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada, Yogyakarta, Indonesia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bines</LastName><ForeName>Julie E</ForeName><Initials>JE</Initials><AffiliationInfo><Affiliation>Enteric Diseases, Murdoch Children's Research Institute, Parkville, Victoria, Australia; Department of Paediatrics, The University of Melbourne, Parkville, Victoria, Australia; Department of Gastroenterology and Clinical Nutrition, Royal Children's Hospital, Parkville, Victoria, Australia. Electronic address: jebines@unimelb.edu.au.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>10</Month><Day>10</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Vaccine</MedlineTA><NlmUniqueID>8406899</NlmUniqueID><ISSNLinking>0264-410X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007070">Immunoglobulin A</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011054">Poliovirus Vaccine, Inactivated</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011055">Poliovirus Vaccine, Oral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C109545">RV3 rotavirus vaccine</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D022243">Rotavirus Vaccines</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007115" MajorTopicYN="N">Immunization Schedule</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000071497" MajorTopicYN="N">Immunogenicity, Vaccine</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007070" MajorTopicYN="N">Immunoglobulin A</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007223" MajorTopicYN="N">Infant</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007231" MajorTopicYN="N">Infant, Newborn</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011051" MajorTopicYN="N">Poliomyelitis</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017955" MajorTopicYN="N">Poliovirus</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011054" MajorTopicYN="N">Poliovirus Vaccine, Inactivated</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011055" MajorTopicYN="N">Poliovirus Vaccine, Oral</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012401" MajorTopicYN="N">Rotavirus</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012400" MajorTopicYN="N">Rotavirus Infections</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D022243" MajorTopicYN="N">Rotavirus Vaccines</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Neonatal</Keyword><Keyword MajorTopicYN="N">Poliovirus</Keyword><Keyword MajorTopicYN="N">Rotavirus</Keyword><Keyword MajorTopicYN="N">Vaccine</Keyword></KeywordList><CoiStatement>CD is a fulltime employee of ViiV Healthcare, all work was completed whilst he was an employee at MCRI. CDK and MCRI hold a patent for the RV3-BB vaccine. RMS and NSB are employees of BioFarma PT who provided funds to support this study and plan to manufacture the RV3-BB vaccine. All other authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>4</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2019</Year><Month>9</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>9</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>10</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>7</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>10</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2019</Year><Month>11</Month><Day>20</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31607604</ArticleId><ArticleId IdType="pmc">PMC6880301</ArticleId><ArticleId IdType="doi">10.1016/j.vaccine.2019.09.071</ArticleId><ArticleId IdType="pii">S0264-410X(19)31299-X</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Bines J.E., Danchin M., Jackson P., Handley A., Watts E., Lee K.J. Safety and immunogenicity of RV3-BB human neonatal rotavirus vaccine administered at birth or in infancy: a randomised, double-blind, placebo-controlled trial. Lancet Infect Dis. 2015;15(12):1389&#x2013;1397.</Citation><ArticleIdList><ArticleId IdType="pubmed">26318715</ArticleId></ArticleIdList></Reference><Reference><Citation>Bines J.E., At Thobari J., Satria C.D., Handley A., Watts E., Cowley D. Human neonatal rotavirus vaccine (RV3-BB) to target rotavirus from birth. N Engl J Med. 2018;378(8):719&#x2013;730.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5774175</ArticleId><ArticleId IdType="pubmed">29466164</ArticleId></ArticleIdList></Reference><Reference><Citation>Burnett E., Jonesteller C.L., Tate J.E., Yen C., Parashar U.D. Global impact of rotavirus vaccination on childhood hospitalizations and mortality from diarrhea. J Infect Dis. 2017;215(11):1666&#x2013;1672.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5543929</ArticleId><ArticleId IdType="pubmed">28430997</ArticleId></ArticleIdList></Reference><Reference><Citation>Chan J., Nirwati H., Triasih R., Bogdanovic-Sakran N., Soenarto Y., Hakimi M. Maternal antibodies to rotavirus: could they interfere with live rotavirus vaccines in developing countries? Vaccine. 2011;29(6):1242&#x2013;1247.</Citation><ArticleIdList><ArticleId IdType="pubmed">21147127</ArticleId></ArticleIdList></Reference><Reference><Citation>Chandola T.R., Taneja S., Goyal N., Antony K., Bhatia K., More D. ROTAVAC((R)) does not interfere with the immune response to childhood vaccines in Indian infants: a randomized placebo controlled trial. Heliyon. 2017;3(5):e00302.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5435614</ArticleId><ArticleId IdType="pubmed">28560356</ArticleId></ArticleIdList></Reference><Reference><Citation>Ciarlet M., Sani-Grosso R., Yuan G., Liu G.F., Heaton P.M., Gottesdiener K.M. Concomitant use of the oral pentavalent human-bovine reassortant rotavirus vaccine and oral poliovirus vaccine. Pediatr Infect Dis J. 2008;27(10):874&#x2013;880.</Citation><ArticleIdList><ArticleId IdType="pubmed">18756184</ArticleId></ArticleIdList></Reference><Reference><Citation>Danchin M., Kirkwood C.D., Lee K.J., Bishop R.F., Watts E., Justice F.A. Phase I trial of RV3-BB rotavirus vaccine: a human neonatal rotavirus vaccine. Vaccine. 2013;31(23):2610&#x2013;2616.</Citation><ArticleIdList><ArticleId IdType="pubmed">23597719</ArticleId></ArticleIdList></Reference><Reference><Citation>Emperador D.M., Velasquez D.E., Estivariz C.F., Lopman B., Jiang B., Parashar U. Interference of monovalent, bivalent, and trivalent oral poliovirus vaccines on monovalent rotavirus vaccine immunogenicity in rural Bangladesh. Clin Infect Dis. 2015;62(2):150&#x2013;156.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4755336</ArticleId><ArticleId IdType="pubmed">26349548</ArticleId></ArticleIdList></Reference><Reference><Citation>Kirkwood C.D., Ma L.F., Carey M.E., Steele A.D. The rotavirus vaccine development pipeline. Vaccine. 2017</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6892263</ArticleId><ArticleId IdType="pubmed">28396207</ArticleId></ArticleIdList></Reference><Reference><Citation>Lewis I., Ottosen A., Rubin J., Blanc D.C., Zipursky S., Wootton E. A supply and demand management perspective on the accelerated global introductions of inactivated poliovirus vaccine in a constrained supply market. J Infect Dis. 2017;216(suppl_1):S33&#x2013;S39.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5853471</ArticleId><ArticleId IdType="pubmed">28838159</ArticleId></ArticleIdList></Reference><Reference><Citation>Parashar U.D., Johnson H., Steele A.D., Tate J.E. Health impact of rotavirus vaccination in developing countries: progress and way forward. Clin Infect Dis. 2016;62(Suppl 2):S91&#x2013;S95.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11343039</ArticleId><ArticleId IdType="pubmed">27059361</ArticleId></ArticleIdList></Reference><Reference><Citation>Patel M., Steele A.D., Parashar U.D. Influence of oral polio vaccines on performance of the monovalent and pentavalent rotavirus vaccines. Vaccine. 2012;30(Suppl 1):A30&#x2013;A35.</Citation><ArticleIdList><ArticleId IdType="pubmed">22520134</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanchez-Uribe E., Esparza-Aguilar M., Parashar U.D., Richardson V. Sustained reduction of childhood Diarrhea-related mortality and hospitalizations in Mexico after rotavirus vaccine universalization. Clin Infect Dis. 2016;62(Suppl 2):S133&#x2013;S139.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11345715</ArticleId><ArticleId IdType="pubmed">27059347</ArticleId></ArticleIdList></Reference><Reference><Citation>Siegrist C.A. Elsevier, Inc; Philadelphia, PA: 2017. Vaccine immunology; pp. 16&#x2013;34.</Citation></Reference><Reference><Citation>Steele A.D., De Vos B., Tumbo J., Reynders J., Scholtz F., Bos P. Co-administration study in South African infants of a live-attenuated oral human rotavirus vaccine (RIX4414) and poliovirus vaccines. Vaccine. 2010;28(39):6542&#x2013;6548.</Citation><ArticleIdList><ArticleId IdType="pubmed">18786585</ArticleId></ArticleIdList></Reference><Reference><Citation>Tregnaghi M.W., Abate H.J., Valencia A., Lopez P., Da Silveira T.R., Rivera L. Human rotavirus vaccine is highly efficacious when coadministered with routine expanded program of immunization vaccines including oral poliovirus vaccine in Latin America. Pediatr Infect Dis J. 2011;30(6):e103&#x2013;e108.</Citation><ArticleIdList><ArticleId IdType="pubmed">21378594</ArticleId></ArticleIdList></Reference><Reference><Citation>Vesikari T., Karvonen A., Forrest B.D., Hoshino Y., Chanock R.M., Kapikian A.Z. Neonatal administration of rhesus rotavirus tetravalent vaccine. Pediatr Infect Dis J. 2006;25(2):118&#x2013;122.</Citation><ArticleIdList><ArticleId IdType="pubmed">16462287</ArticleId></ArticleIdList></Reference><Reference><Citation>Wahjuhono G., Revolusiana D., Widhiastuti J., Sundoro T., Mardani W.U., Ratih R. Switch from oral to inactivated poliovirus vaccine in Yogyakarta Province, Indonesia: summary of coverage, immunity, and environmental surveillance. J Infect Dis. 2014;210(Suppl 1):S347&#x2013;S352.</Citation><ArticleIdList><ArticleId IdType="pubmed">25316854</ArticleId></ArticleIdList></Reference><Reference><Citation>Weldon Standard Methods fpr detection of poliovirus antibodies. Methods Mol Biol. 2016;1387:145&#x2013;176.</Citation><ArticleIdList><ArticleId IdType="pubmed">26983734</ArticleId></ArticleIdList></Reference><Reference><Citation>WHO. Polio eradication &amp; endgame strategic plan 2013&#x2013;2018; 2013. Retrieved 28/03/2018, 2018, from http://polioeradication.org/wp-content/uploads/2016/07/PEESP_EN_A4.pdf.</Citation></Reference><Reference><Citation>WHO. Rotavirus vaccines; WHO position paper-January 2013; 2013, vol. 88. p. 49&#x2013;64.</Citation><ArticleIdList><ArticleId IdType="pubmed">0</ArticleId></ArticleIdList></Reference><Reference><Citation>Zaman K., Sack D.A., Yunus M., Arifeen S.E., Podder G., Azim T. Successful co-administration of a human rotavirus and oral poliovirus vaccines in Bangladeshi infants in a 2-dose schedule at 12 and 16 weeks of age. Vaccine. 2009;27(9):1333&#x2013;1339.</Citation><ArticleIdList><ArticleId IdType="pubmed">19162114</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>